US Pharma MarketingDimerix buys a kidney injury drug; Arpeggio appears to be winding down
Plus, news about Takeda, Novartis and Regenxbio. 🤝 Mission sells kidney injury drug to Dimerix: Dimerix will pay $5 million upfront for Mission’s Phase 2-ready candidate for acute kidney injury, known ...
Plus, news about Takeda, Novartis and Regenxbio.
🤝 Mission sells kidney injury drug to Dimerix: Dimerix will pay $5 million upfront for Mission’s Phase 2-ready candidate for acute kidney injury, known ...
Source: Endpoints News